4-HO-DALT
4-HO-DALT, also known as 4-hydroxy-N,''N''-diallyltryptamine or as daltocin, is a serotonin receptor agonist and serotonergic psychedelic of the tryptamine and 4-hydroxytryptamine families. It has been encountered as a novel designer drug.4-HO-DALT was not included nor mentioned in Alexander Shulgin's book TiHKAL. However, in a subsequently released entry, it was briefly mentioned. He does not appear to have synthesized or tested it and its properties were not described, but Shulgin hypothesized that the drug, in its prodrug form 4-AcO-DALT, would have a very rapid onset of action. Subsequently, 4-HO-DALT has emerged as a novel designer drug. It is said to produce hallucinogenic effects similar to those of 4-HO-DiPT and 4-HO-DPT.Interactions
Pharmacology
Pharmacodynamics
4-HO-DALT binds to many of the serotonin receptors, including the serotonin 5-HT2A receptor, as well as other targets. The drug acts as a potent full agonist of the serotonin 5-HT2A and 5-HT2B receptors, whereas it showed 60-fold lower potency as an agonist of the serotonin 5-HT2C receptor compared to the serotonin 5-HT2A receptor. It produces the head-twitch response, a behavioral proxy of psychedelic-like effects, in rodents.Chemistry
Analogues
s of 4-HO-DALT include diallyltryptamine, 4-AcO-DALT, 5-MeO-DALT, 4-HO-MALT, psilocin, 4-HO-DET, 4-HO-DPT, and 4-HO-DiPT, among others.History
4-HO-DALT was first described by Alexander Shulgin in a follow-up entry of TiHKAL in 2004. Subsequently, it was further described in 2017 and thereafter. The drug was encountered online as a novel designer drug by 2014. In 2023, it was found to be sold as an analytical standard.Society and culture
4-HO-DALT is not a controlled substance in Canada as of 2025.